Century Therapeutics Inc Offer Shares at $18 to $20

Century Therapeutics Inc. set terms for its initial public offering on Monday, with plans to offer 10.6 million shares priced at $18 to $20 each. The company has applied to the list on Nasdaq, under the ticker symbol “IPSC.

JP Morgan, BofA Securities, SVB Leerink and Piper Sandler are underwriting the deal. Proceeds will be used to fund pre-clinical activity and research and development, as well as working capital and general corporate purposes. We are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and haematological malignancies with significant unmet medical need.

Century Therapeutics Inc a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Alessandro Riva, M.D., and Kimberly Blackwell, M.D., as new Independent Directors.Century Therapeutics Inc is curbing the power of adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care.

The company is expanding its presence in uCity Square, opening 17,000 square feet of mixed office and laboratory space at 3624 Market Street, an additional 5,000 square feet of space at 3711 Market Street and has signed a lease for 25,000 square feet at 3535 Market Street within steps of the current headquarters at 3675 Market Street. Century has also committed to 33,000 square feet in the One uCity life sciences development currently under construction in the same burgeoning region of the city.